Invest in the Future of Dermatology

Skin diseases like psoriasis, eczema, and mycosis fungoides affect millions worldwide, creating a significant burden on healthcare systems and deeply impacting patients’ quality of life. Yet, diagnostic methods remain unchanged, relying on visual assessments and histology. This gap often leads to misdiagnoses, delayed treatments, and increased healthcare costs. At Dermagnostix, we see this not as a challenge but as an opportunity to lead a transformative change in dermatology diagnostics.

As pioneers in molecular diagnostics, we’ve developed a fully automated platform that delivers precise and objective results directly at the Point-of-need. Our flagship product, PsorX-LabDisk, is the world’s first molecular test differentiating psoriasis from eczema, empowering clinicians with faster, more accurate tools to make life-changing decisions. Our innovative pipeline also includes diagnostics for early mycosis fungoides detection and inflammatory disease profiling, setting new standards in dermatopathology.

Investing in Dermagnostix is a chance to leave a legacy of innovation and compassion. It means joining a mission to improve patient’s lives while revolutionizing dermatology diagnostics. By partnering with us, you support innovative healthcare solutions that save time, reduce uncertainty, and profoundly improve patient outcomes. Your investment fuels the future of healthcare, driving breakthroughs that make diagnostics faster, more accessible, and more reliable for those who need it most.

Together, we can shape a future where every patient benefits from accurate, personalized care. We can redefine dermatology and create a healthier, more confident future for patients worldwide. Join us in transforming the way skin diseases are diagnosed, treated, and understood.